Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Bioventix ( (GB:BVXP) ) has shared an update.
Bioventix plc reported that its Chief Financial Officer, Bruce Hiscock, purchased 126 ordinary shares in the company on 2 April 2026 at a price of 1,622 pence per share. Following this transaction, Hiscock’s total beneficial holding increased to 1,600 shares, representing about 0.03% of the company’s issued share capital, signalling a modest vote of confidence in the business from a senior executive and complying with market abuse regulation disclosure rules.
The most recent analyst rating on (GB:BVXP) stock is a Buy with a £1658.00 price target. To see the full list of analyst forecasts on Bioventix stock, see the GB:BVXP Stock Forecast page.
Spark’s Take on BVXP Stock
According to Spark, TipRanks’ AI Analyst, BVXP is a Outperform.
The score is driven primarily by very strong financial quality (high profitability, strong cash conversion, and no debt). This is tempered by weak technicals (price below key moving averages with negative MACD) and signs of slowing operating momentum in 2025. Valuation and dividend yield are supportive, while corporate updates are mixed (insider buying versus revenue/profit pressure).
To see Spark’s full report on BVXP stock, click here.
More about Bioventix
Bioventix plc is a UK-based life sciences company that specialises in developing and commercially supplying high-affinity monoclonal antibodies used in clinical diagnostic tests. Its products support in vitro diagnostics manufacturers and laboratories, providing critical reagents for blood testing and other medical assay applications worldwide.
Average Trading Volume: 9,311
Technical Sentiment Signal: Sell
Current Market Cap: £84.9M
Find detailed analytics on BVXP stock on TipRanks’ Stock Analysis page.